Skip to Main Content

Author Details

Luis J Montaner
Wistar Institute
1958
232
47
Sarah J Ratcliffe (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
35979886"I Know That I Was a Part of Making a Difference": Participant Motivations for Joining a Cure-Directed HIV Trial with an Analytical Treatment Interruption.AIDS Res Hum Retroviruses2023
37837376Participant experiences in HIV cure-directed trial with an extended analytical treatment interruption in Philadelphia, United States.HIV Res Clin Pract2023
37291622Community engagement group model in basic and biomedical research: lessons learned from the BEAT-HIV Delaney Collaboratory towards an HIV-1 cure.Res Involv Engagem2023
36975214The Natural Stilbenoid (-)-Hopeaphenol Inhibits HIV Transcription by Targeting Both PKC and NF-κB Signaling and Cyclin-Dependent Kinase 9.Antimicrob Agents Chemother2023
37070542Susceptibility to 3BNC117 and 10-1074 in ART suppressed chronically infected persons.AIDS2023
36963401Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis.Cancer Cell2023
37463049The latent reservoir of inducible, infectious HIV-1 does not decrease despite decades of antiretroviral therapy.J Clin Invest2023
36807444Tissue injury and leukocyte changes in post-acute sequelae of SARS-CoV-2: review of 2833 post-acute patient outcomes per immune dysregulation and microbial translocation in long COVID.J Leukoc Biol2023
36460646Human galectin-9 promotes the expansion of HIV reservoirs in vivo in humanized mice.AIDS2023
36799121Using a Bioactive <i>Eremophila</i>-Derived Serrulatane Scaffold to Generate a Unique Carbamate Library for Anti-infective Evaluations.J Nat Prod2023
36657039Thorectidiol A Isolated from the Marine Sponge <i>Dactylospongia elegans</i> Disrupts Interactions of the SARS-CoV-2 Spike Receptor Binding Domain with the Host ACE2 Receptor.J Nat Prod2023
35017208The Minority Scientists' Experience: Challenging and Overcoming Barriers to Enhancing Diversity and Career Advancement.J Immunol2022
35348047"We are looking at the future right now": community acceptability of a home-based viral load test device in the context of HIV cure-related research with analytical treatment interruptions in the United States.HIV Res Clin Pract2022
35730977Inhibition of a Chromatin and Transcription Modulator, SLTM, Increases HIV-1 Reactivation Identified by a CRISPR Inhibition Screen.J Virol2022
35399717ONP-302 Nanoparticles Inhibit Tumor Growth By Altering Tumor-Associated Macrophages And Cancer-Associated Fibroblasts.J Cancer2022
35419694Use of hyphenated analytical techniques to identify the bioactive constituents of Gunnera perpensa L., a South African medicinal plant, which potently inhibit SARS-CoV-2 spike glycoprotein-host ACE2 binding.Anal Bioanal Chem2022
35522580Ansellone J, a Potent <i>in Vitro</i> and <i>ex Vivo</i> HIV-1 Latency Reversal Agent Isolated from a <i>Phorbas</i> sp. Marine Sponge.J Nat Prod2022
35968737Participant experiences using novel home-based blood collection device for viral load testing in HIV cure trials with analytical treatment interruptionsHIV Res Clin Pract2022
35891417HPLC-Based Purification and Isolation of Potent Anti-HIV and Latency Reversing Daphnane Diterpenes from the Medicinal Plant <i>Gnidia sericocephala</i> (<i>Thymelaeaceae</i>).Viruses2022
36220073Peroxynitrite in the tumor microenvironment changes the profile of antigens allowing escape from cancer immunotherapy.Cancer Cell2022
35916053Methadone use is associated with increased levels of sCD14, immune activation, and inflammation during suppressed HIV infection.J Leukoc Biol2022
35320704Single-cell multiomics reveals persistence of HIV-1 in expanded cytotoxic T cell clones.Immunity2022
35207719Preliminary Acceptability of a Home-Based Peripheral Blood Collection Device for Viral Load Testing in the Context of Analytical Treatment Interruptions in HIV Cure Trials: Results from a Nationwide Survey in the United States.J Pers Med2022
33441429Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption.Sci Transl Med2021
33622719Phospholipid Metabolism Is Associated with Time to HIV Rebound upon Treatment Interruption.mBio2021
33527127Intact Human Immunodeficiency Virus (HIV) Reservoir Estimated by the Intact Proviral DNA Assay Correlates With Levels of Total and Integrated DNA in the Blood During Suppressive Antiretroviral Therapy.Clin Infect Dis2021
33577894Flavonoid-based inhibition of cyclin-dependent kinase 9 without concomitant inhibition of histone deacetylases durably reinforces HIV latency.Biochem Pharmacol2021
34543092The Natural Stilbenoid (-)-Hopeaphenol Inhibits Cellular Entry of SARS-CoV-2 USA-WA1/2020, B.1.1.7, and B.1.351 Variants.Antimicrob Agents Chemother2021
34447895Lack of Atorvastatin Effect on Monocyte Gene Expression and Inflammatory Markers in HIV-1-infected ART-suppressed Individuals at Risk of non-AIDS Comorbidities.Pathog Immun2021
34188039Non-invasive plasma glycomic and metabolic biomarkers of post-treatment control of HIV.Nat Commun2021
34117731Immune correlates of therapy outcomes in women with cervical cancer treated with chemoradiotherapy: A systematic review.Cancer Med2021
34339980Design, synthesis and screening of a drug discovery library based on an Eremophila-derived serrulatane scaffold.Phytochemistry2021
34287839BCL6 BTB-specific inhibitor reversely represses T-cell activation, Tfh cells differentiation, and germinal center reaction in vivo.Eur J Immunol2021
34086344Identification of the predominant human NK cell effector subset mediating ADCC against HIV-infected targets coated with BNAbs or plasma from PLWH.Eur J Immunol2021
34049356Comparable HIV suppression by pegylated-IFN-α2a or pegylated-IFN-α2b during a 4-week analytical treatment interruption.AIDS2021
33436641Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy.Nat Commun2021
33408173Increased Proviral DNA in Circulating Cells Correlates with Plasma Viral Rebound in Simian Immunodeficiency Virus-Infected Rhesus Macaques after Antiretroviral Therapy Interruption.J Virol2021
33449236HIV Infection and Depression Among Opiate Users in a US Epicenter of the Opioid Epidemic.AIDS Behav2021
33323024Safety, Immune, and Antiviral Effects of Pegylated Interferon Alpha 2b Administration in Antiretroviral Therapy-Suppressed Individuals: Results of Pilot Clinical Trial.AIDS Res Hum Retroviruses2021
31571234BCL6 BTB-specific inhibition via FX1 treatment reduces Tfh cells and reverses lymphoid follicle hyperplasia in Indian rhesus macaque (Macaca mulatta).J Med Primatol2020
31972605Plasma and antibody glycomic biomarkers of time to HIV rebound and viral setpoint.AIDS2020
33378668Distinct Populations of Immune-Suppressive Macrophages Differentiate from Monocytic Myeloid-Derived Suppressor Cells in Cancer.Cell Rep2020
33239444Autologous IgG antibodies block outgrowth of a substantial but variable fraction of viruses in the latent reservoir for HIV-1.Proc Natl Acad Sci U S A2020
33098533Correction to: Effect of Opioid Use on Immune Activation and HIV Persistence on ART.J Neuroimmune Pharmacol2020
33289158Persons who inject drugs (PWID) retain functional NK cells, dendritic cell stimulation, and adaptive immune recall responses despite prolonged opioid use.J Leukoc Biol2020
32690683Intact proviral DNA assay analysis of large cohorts of people with HIV provides a benchmark for the frequency and composition of persistent proviral DNA.Proc Natl Acad Sci U S A2020
32827942Interferon-α alters host glycosylation machinery during treated HIV infection.EBioMedicine2020
32675559Hepatitis C virus modulates IgG glycosylation in HIV co-infected antiretroviral therapy suppressed individuals.AIDS2020
32788215The African natural product knipholone anthrone and its analogue anthralin (dithranol) enhance HIV-1 latency reversal.J Biol Chem2020
32895573Recommendations for measuring HIV reservoir size in cure-directed clinical trials.Nat Med2020
  • 1 - 50 of 232

Recommended Authors

University of California San Francisco
Career Start Year 2012
Number of shared co-authors 7
Vaccine & Gene Therapy Institute, Oregon Health & Science University
Career Start Year 2010
Number of shared co-authors 4
University of California San Francisco
Career Start Year 2008
Number of shared co-authors 2
Massachusetts General Hospital/Harvard Medical School
Career Start Year 2006
Number of shared co-authors 5
Noguchi Memorial Institute for Medical Research, University of Ghana
Career Start Year 2004
Number of shared co-authors 0
Goethe University Frankfurt, University Hospital
Career Start Year 2003
Number of shared co-authors 0
University of California San Francisco
Career Start Year 2002
Number of shared co-authors 7
University of California san francisco
Career Start Year 2002
Number of shared co-authors 11
Vitalant Research Institute
Career Start Year 2001
Number of shared co-authors 4
Vitalant Research Institute, USA University of California san francisco
Career Start Year 2001
Number of shared co-authors 9
George Washington University
Career Start Year 2000
Number of shared co-authors 5
University of California San Francisco
Career Start Year 1999
Number of shared co-authors 3
&quotMagna Graecia&quot University
Career Start Year 1998
Number of shared co-authors 4
Ragon Institute of MGH
Career Start Year 1995
Number of shared co-authors 8
The University of Melbourne at the Peter Doherty Institute for Infection and Immunity
Career Start Year 1993
Number of shared co-authors 16
University College London
Career Start Year 1992
Number of shared co-authors 1
Harvard School of Public Health
Career Start Year 1989
Number of shared co-authors 4
La Paz University Hospital
Career Start Year 1988
Number of shared co-authors 3
Instituto de Investigacion Hospital 12 de Octubre (imas12)
Career Start Year 1988
Number of shared co-authors 1
University Medical Center Utrecht
Career Start Year 1988
Number of shared co-authors 3
University of Cincinnati
Career Start Year 1988
Number of shared co-authors 6
University of Nebraska Medical Center
Career Start Year 1987
Number of shared co-authors 5
National Institute of Allergy and Infectious Diseases, National Institutes of Health
Career Start Year 1985
Number of shared co-authors 8
University of Washington
Career Start Year 1984
Number of shared co-authors 11
Vanderbilt University Medical Center
Career Start Year 1983
Number of shared co-authors 0
Division of Clinical Research, National Institutes of Allergy and Infectious Diseases
Career Start Year 1981
Number of shared co-authors 6
Case Western Reserve University
Career Start Year 1981
Number of shared co-authors 2
Northwestern University Feinberg School of Medicine
Career Start Year 1979
Number of shared co-authors 14
Vir Biotechnology Inc.
Career Start Year 1977
Number of shared co-authors 7
Frederick National Laboratory
Career Start Year 1977
Number of shared co-authors 13

Collaborators

Co-authored papers 57
Perelman School of Medicine, University of Pennsylvania
Co-authored papers 29
The Wistar Institute
Co-authored papers 13
Perelman School of Medicine, University of Pennsylvania
Co-authored papers 11
Wistar Institute
Co-authored papers 11
The Wistar Institute
Co-authored papers 9
IF School of Medicine, University of Pennsylvania
Co-authored papers 8
University of Pennsylvania School of Medicine
Co-authored papers 8
University of California san francisco
Co-authored papers 8
Perelman School of Medicine, University of Pennsylvania
Co-authored papers 7
Merck & Co. Inc.
Co-authored papers 7
Co-authored papers 6
Johns Hopkins University School of Medicine
Co-authored papers 6
Icahn School of Medicine at Mount Sinai
Co-authored papers 5
Center for AIDS Research, University of California San Diego
Co-authored papers 5
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Co-authored papers 4
Frederick National Laboratory for Cancer Research, National Cancer Institute
Co-authored papers 3
Co-authored papers 3
Co-authored papers 3
Co-authored papers 3
Co-authored papers 3
Merck & Co. Inc.
Co-authored papers 3
Vitalant Research Institute
Co-authored papers 2
Co-authored papers 2
Co-authored papers 2
University of Pennsylvania Department of Pathology & Laboratory Medicine
Co-authored papers 2
University of Pennsylvania Perelman School of Medicine
Co-authored papers 2
University of Virginia
Co-authored papers 2
Foundational Immunology, AbbVie Cambridge Research Center
Co-authored papers 2
Johns Hopkins Bloomberg School of Public Health
Co-authored papers 2